Latest Breaking News On - Insider transactions at apellis pharmaceuticals - Page 1 : comparemela.com

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Receives $76 67 Consensus Price Target from Analysts

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Receives $76 67 Consensus Price Target from Analysts
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesRobertw bairdCedric francoisPascal deschateletsInstitutional investors weigh in on apellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticalsAnalyst recommendations for apellis pharmaceuticalsFirst horizon advisors incApellis pharmaceuticals price performanceApellis pharmaceuticals company profileInsider transactions at apellis pharmaceuticalsSecurities exchange commissionApellis pharmaceuticals incNeedham companyFinancial wealth managment

AGF Management Ltd Lowers Holdings in Apellis Pharmaceuticals, Inc (NASDAQ:APLS)

AGF Management Ltd Lowers Holdings in Apellis Pharmaceuticals, Inc (NASDAQ:APLS)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Nur nicholsonCedric francoisExchange commissionPolar capital holdings plcAgf management ltdManagement ltdApellis pharmaceuticals tradingVictory capital management incJpmorgan chase coApellis pharmaceuticals company profileQuarter for apellis pharmaceuticalsJennison associatesFiera capital corpInsider transactions at apellis pharmaceuticalsJefferies financial groupNews ratings for apellis pharmaceuticals daily

Apellis Pharmaceuticals (NASDAQ:APLS) Announces Quarterly Earnings Results, Hits Estimates

Apellis Pharmaceuticals (NASDAQ:APLS) Announces Quarterly Earnings Results, Hits Estimates
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Timothy eugene sullivanRaymond jamesDavido watsonApellis pharmaceuticals stock performanceApellis pharmaceuticalsApellis pharmaceuticals incNews ratings for apellis pharmaceuticals dailyEarnings history for apellis pharmaceuticalsGoldman sachs groupInsider transactions at apellis pharmaceuticalsSecurities exchange commissionGet free reportEugene sullivanExchange commissionGeneral counsel davidApellis pharmaceuticals daily

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3 5% After Analyst Downgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]

United statesCedric francoisRaymond jamesPascal deschateletsApellis pharmaceuticals stock downInsider transactions at apellis pharmaceuticalsApellis pharmaceuticals company profileProfund advisorsApellis pharmaceuticalsApellis pharmaceuticals incCharles schwab investment management incAmerican investors coNews ratings for apellis pharmaceuticals dailyInstitutional trading of apellis pharmaceuticalsGoldman sachs groupJefferies financial group

Brokerages Set Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Price Target at $78 60

Brokerages Set Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Price Target at $78 60
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesCedric francoisPascal deschateletsSecurities exchange commissionProfund advisorsApellis pharmaceuticals incNews ratings for apellis pharmaceuticals dailyCharles schwab investment management incJefferies financial groupNeedham companyWynnefield capital incApellis pharmaceuticals stockAmerican investors coInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticalsInsider transactions at apellis pharmaceuticals